NEW FDA Kava
Warnings: How Safe is it?
Hyla Cass,
MD
April 2, 2002
The Food and Drug Administration (FDA) is advising
consumers of the potential risk of liver damage associated with
the use of kava-containing dietary supplements. Indigenous to the
islands in the South Pacific, kava (Piper methysticum) has
become one of the top-selling herbs in the U.S., ranking ninth
in retail sales in 2000. Kava's widespread popularity is based
on its well-recognized ability to safely relieve stress, anxiety
and tension sleeplessness, menopausal symptoms and other conditions.
Kava came under the scrutiny of the United States
Food and Drug Administration (FDA) after a number of European reports
that it might cause damage to the liver - including hepatitis,
cirrhosis, and liver failure. German and Swiss health authorities
have identified approximately 30 such cases, including four cases
requiring transplantation, and one death. As a result, regulatory
agencies in Germany, Switzerland, France, Canada, and the United
Kingdom, have taken actions ranging from warning consumers about
the potential risks of kava use, to removing kava-containing products
from the marketplace. In the U.S., FDA has received several reports
of kava-related liver damage, including a report of a previously
healthy young woman who required a liver transplant. Although the
incidence appears to be rare, FDA believes consumers should be
informed of potential risks (see box below).
The Evidence So Far
Concerned by these reports, a coalition of U.S.
trade associations from the dietary supplement and herbal industry
responded by hiring a highly regarded professional toxicologist
to evaluate the potential relationship between kava consumption
and liver problems. After carefully analyzing the available data,
his final report concluded that, based on the lack of specific
clinical and historical information, "there is no clear evidence
that the liver damage reported in the U.S. and Europe was caused
by the consumption of kava." Additionally the report found that,
even in instances of possible association between kava and liver
damage, the cases appear to have been hypersensitivity or idiosyncratic-based
responses. It also was shown that the vast majority 30 European
cases, 21 in all, involved the concomitant use of hepatotoxic drugs
and/or alcohol.
The report concluded that the medical community
and the general public should be informed that kava should not
be taken in conjunction with prescription drugs associated with
liver damage, excessive alcohol consumption, and by those with
pre-existing liver disease or with compromised liver function.
At the same time, attention was drawn to two specific cases of
consumption of very large quantities of kava, that, from a toxicological
perspective, provide some evidence that kava itself is not a direct
hepatotoxin, even in extremely high concentrations."
Research Results Show High Level of Safety
Prior research bears out his conclusions. Kava
has a long tradition of safe use in the South Pacific as a ceremonial
and medicinal drink, often at considerably higher doses than those
used in Europe. In fact, the safety and toxicity of kava has been
extensively studied in recent years, with very few reported liver
toxic effects.
The longest running study conducted to date, with
101 people for 6 months taking 70 mg 3 times a day had negligible
side effects, and in fact, the placebo group reported more side
effects than those taking the kava. The researcher concluded that,
in contrast to both benzodiazapines and antidepressants, kava possesses
an excellent side-effect profile.
The safe and effective benefits of kava to relieve
symptoms of anxiety were also supported in a meta-analysis, a systematic
statistical review of seven human clinical trials published in
2000 in the Journal of Clinical Psychopharmacology, and again in
a similar critical review in 2001. The reviews did not find significant
adverse effects related to liver toxicity. In addition, a recent
clinical study by Professor Jonathan Davidson and Dr. Kathryn Connor
from Duke University, showed no liver abnormalities or other significant
side effects.
In 1990 the German government's Commission E -
a commissioned panel of experts in the fields of medicine and pharmacy
- evaluated the scientific and medical literature. Their conclusion
was that kava should be approved as a nonprescription medicine
for "nervous anxiety, stress, and restlessness."
Kava Safer Than Conventional and OTC Drugs
The large number of published safety and toxicity
studies clearly indicate that kava is far safer - and less hepatotoxic
- than conventional pharmaceutical anti-anxiety and antidepressant
prescription drugs.
For example, one is far likelier to suffer liver
damage from the prescription anti-anxiety drug, Valium, which also
carries the risk of other serious side effects, such as addiction
and concomitant withdrawal symptoms that can include seizures.
Additionally, the leading single cause of liver
failure in Western countries is overdose of the common pain medication,
acetominophen (Tylenol). In fact, acetominophen overdose patients
are placed in a special category as candidates for liver transplant
because the speed of liver damage requires immediate treatment.
Despite the fact that prescription and over-the-counter
drugs such Valium and acetominophen are taken by millions daily,
there is very little public question as to their safety - and virtual
no major adverse publicity.
Conclusion While a more thorough investigation
is needed before drawing any final conclusions about kava's potential
toxicity, this issue underscores the importance - and the vulnerability
- of the liver. The liver is the body's principle chemical factory,
responsible for a complex array of duties ranging from detoxification
of ingested chemicals and filtering waste products to metabolizing
nutrients for energy and storing excess energy for later conversion
into fuel.
Ironically, while the topic here is the potential
hepatotoxicity of an herb, the plant kingdom provides us with such
life-saving liver-protective herbs as milk thistle. In fact, in
my clinical practice I include milk thistle in the regimen of clients
who have been exposed to liver-damaging drugs, both to protect
the liver and to restore its vital function.
The current situation does point out that the
liver is affected by many substances, including prescription and
non- prescription drugs, as well as alcohol, which is a major cause
of liver damage.
We must be aware that herbs are potent medicines,
to be treated with the appropriate respect regarding potential
interactions and toxicity, including to the liver. That being said,
kava's margin of safety far surpasses that of its pharmaceutical
equivalent. Nothing would be gained by previously satisfied consumers
of kava, out of fear of these potential side effects, switching
to a more toxic prescription medication, such as a benzodiazepine,
in the mistaken belief that they were making a safer choice.
Kava Recommendations
In the interest of safety, until more details are
known, the FDA recommends, and we concur, that consumers
of kava consider the following:
- Kava should not be used by anyone who has any
liver problems, or by anyone who is taking any
drug product with known adverse effects on the
liver, or anyone who is a regular consumer of alcohol.
- Consumers should discontinue use if symptoms
of jaundice (e.g., dark urine, yellowing of the
eyes) occur.
- Consumers should consult their primary healthcare
provider if they have a history of liver problems
or suspect possible liver problems before using
kava or continuing its use.
- Since the reports so far are associated with
chronic use, we suggest that kava not be taken
on a daily basis for more that 3 months, which
is in keeping with the German Commission E's recommendation.
- Given that adverse reactions have been reported
in Germany, where higher doses above recommended
levels are routinely prescribed, we further recommend
a maximum intake of 125 mg kavalactones per tablet
or capsule, 3g of dried rhizome per teabag, and
250 mg kavalactones maximum daily dose for all
forms.
|
|
|